Soft Tissue Sarcoma
Conditions
Brief summary
This study is a open-lable , single arm，single center, phase II clinical study. Target population is patients with high-risk Soft tissue sarcoma. Study objective is to compare the efficacy and safety of camrelizumab in combination with Liposome doxorubicin and Ifosfamide in study population in China. Camrelizumab is a humanized anti-PD1 IgG4 monoclonal antibody.
Detailed description
In this study, eligible subject will be enrolled into study arm to accept study treatment. Treatment cycles of chemotherapy will be at most 8 cycles which will be decided by investigators. Objective response rate will be the primary outcome measures.
Interventions
camrelizumab in combination with Liposome doxorubicin and Ifosfamide
Sponsors
Jiangsu HengRui Medicine Co., Ltd.
Sun Yat-sen University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
14 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
1. Age 14 to 65 year old; 2. Eastern Cooperative Oncology Group performance status 0-1; 3. The high-risk soft tissue sarcoma of limbs or trunk (FNCLCC grade 3 or FNCLCC grade2 but imaging evaluation showed that it was more than 50% necrosis; more than 5cm; deep tumor), including synovial sarcoma, undifferentiated pleomorphic sarcoma / malignant fibrous histiocytoma, pleomorphic rhabdomyosarcoma, round cell /Myxiod liposarcoma，Malignant peripheral nerve sheath tumors, etc; 4. Patients with soft tissue sarcoma who are ready for neoadjuvant chemotherapy need to meet the following conditions: 1. According to the evaluation, the patients who received neoadjuvant chemotherapy can achieve standard resection of tumor 2. If important structures (blood vessels and nerves) are involved, radical operation cannot be performed 5. Having measurable lesion according to RECIST 1.1 6. Life expectancy \>3 months 7. Patients must have adequate organ function 8. Fertile men and women of childbearing potential must agree to use an effective method of birth control from providing signed consent and for 120 days after last study drug administration. Women of childbearing potential must have a negative pregnancy test ≤ 72 hours prior to Day 1 of study 9. Voluntary informed consent , joining the study with good compliance
Exclusion criteria
* 1\. pregnant or lactating women 2. Known history of hypersensitivity to any components of the camrelizumab formulation, or other antibody formulation. 3\. Active central nervous system (CNS) metastases with clinical symptoms , including cerebral edema, steroid requirement, or progressive disease. 4\. Patients with other malignant tumor within 5 years , except cured skin basal cell carcinoma, cervical carcinoma and Papillary carcinoma of thyroid. 5\. Clinically significant cardiovascular diseases 6. Have received any of the following treatments： 1. Patients have had prior treatment with PD-1/PD-L1 or CTLA-4 antagonists. 2. Received any study drug within 4 weeks prior to the first study drug administration. 3. Enroll in another clinical study, unless it is an observational (non-interventional) clinical study or an intervention follow-up study. 4. Concurrent medical condition requiring the use of immunosuppressive medications, or immunosuppressive doses of systemic or absorbable topical corticosteroids. 5. Doses \> 10 mg/day prednisone or equivalent are prohibited within 2 weeks before study drug administration. Note: corticosteroids used for the allergy and nausea, vomiting are allowed. Inhaled or topical use of steroids and adrenocorticosteroid replacement in doses greater than 10mg/ day is permitted in the absence of active autoimmune disease. 6. Patients who have received a live vaccine within 30 days prior to the first study drug administration. 7. Major surgery or major trauma within 4 weeks of first study drug administration. Left ventricular ejection fraction (LVEF) is more than 60% . 7\. Severe infection occurred within 4 weeks before the first study drug administration (CTC AE \> grade 2) 8. Patients with any active autoimmune disease or history of autoimmune disease, including but not limited to the following: hepatitis, pneumonitis, uveitis, colitis (inflammatory bowel disease), hypophysitis, vasculitis, nephritis, hyperthyroidism, and hypothyroidism except for subjects with vitiligo or resolved childhood asthma/atopy. Asthma that requires intermittent use of bronchodilators or other medical intervention should also be excluded. Stable dose of insulin for type 1 diabetes. 9\. History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or organ transplantation and bone marrow transplantation. 10\. Objective evidence of previous or current pulmonary fibrosis history, interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, pulmonary function damaged seriously etc. 11\. History of active pulmonary tuberculosis infection, or with a history of active pulmonary tuberculosis infection within 1 year prior to enrollment, or with a history of active pulmonary tuberculosis infection prior to 1 year but without formal treatment. 12\. Active hepatitis (transaminase does not meet the inclusion, hepatitis B virus (HBV) DNA ≥10⁴ /ml or hepatitis C virus (HCV) RNA≥103 /ml or higher); Chronic hepatitis B virus carriers who HBV DNA\<2000 IU/ml(\<104/ml), must receive anti-viral treatment throughout the study. 13\. Known history of psychotropic substance abuse, alcohol abuse and drug abuse. 14\. The investigators did not think the participants were suitable for inclusion.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Objective response rate | 24 months | ORR |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 2 years Overall Survival (OS) rate | 24 months | The percentage of patients overall survival in 2 years |
| 2 years Progression-free survival (PFS) rate | 24 months | The percentage of patients Progression-free survival in 2 years |
| Adverse Events (AEs) | 24 months | All adverse event/Serious adverse event that occurred during the study period according to CTCAE |
Countries
China
Contacts
Primary ContactJin Wang, MD
Outcome results
None listed